Merck & Company, Inc. (NYSE:MRK)‘s stock had its “buy” rating restated by BMO Capital Markets in a report released on Friday. They presently have a $72.00 price objective on the stock. BMO Capital Markets’ price target indicates a potential upside of 12.03% from the stock’s current price.

Several other research firms have also commented on MRK. Credit Suisse Group set a $72.00 price target on Merck & and gave the stock a “buy” rating in a research report on Tuesday, June 6th. BidaskClub lowered Merck & from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Vetr lowered Merck & from a “strong-buy” rating to a “buy” rating and set a $69.99 price target for the company. in a research report on Wednesday, May 17th. Cowen and Company restated a “hold” rating and set a $70.00 price target on shares of Merck & in a research report on Friday, September 1st. Finally, UBS AG raised their price target on Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $69.56.

Merck & (MRK) opened at 64.27 on Friday. The stock has a market cap of $175.29 billion, a PE ratio of 34.80 and a beta of 0.81. The company’s 50-day moving average price is $62.97 and its 200-day moving average price is $63.73. Merck & has a 12-month low of $58.29 and a 12-month high of $66.80.

Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.87 by $0.14. The company had revenue of $9.93 billion during the quarter, compared to analyst estimates of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.93 earnings per share. On average, equities analysts expect that Merck & will post $3.88 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/10/merck-company-inc-mrk-stock-rating-reaffirmed-by-bmo-capital-markets.html.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Klingenstein Fields & Co. LLC grew its holdings in shares of Merck & by 5.4% during the first quarter. Klingenstein Fields & Co. LLC now owns 446,450 shares of the company’s stock worth $28,368,000 after buying an additional 22,958 shares during the last quarter. First PREMIER Bank grew its holdings in shares of Merck & by 2.7% during the first quarter. First PREMIER Bank now owns 21,475 shares of the company’s stock worth $1,364,000 after buying an additional 570 shares during the last quarter. Agran Libbie grew its holdings in shares of Merck & by 83.0% during the first quarter. Agran Libbie now owns 11,918 shares of the company’s stock worth $757,000 after buying an additional 5,404 shares during the last quarter. Stevens Capital Management LP purchased a new position in shares of Merck & during the first quarter worth about $15,126,000. Finally, Doyle Wealth Management purchased a new position in shares of Merck & during the first quarter worth about $4,652,000. Institutional investors and hedge funds own 73.02% of the company’s stock.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.